



Published in final edited form as:

ACS Chem Neurosci. 2015 July 15; 6(7): 1248–1258. doi:10.1021/acchemneuro.5b00094.

## Serotonin (5-HT) 5-HT<sub>2A</sub> Receptor (5-HT<sub>2A</sub>R):5-HT<sub>2C</sub>R Imbalance in Medial Prefrontal Cortex Associates with Motor Impulsivity

Noelle C. Anastasio<sup>1,2</sup>, Sonja J. Stutz<sup>1</sup>, Latham H. L. Fink<sup>1</sup>, Sarah E. Swinford-Jackson<sup>1</sup>, Robert M Sears<sup>3</sup>, Ralph J. DiLeone<sup>3</sup>, Kenner C. Rice<sup>4</sup>, F. Gerard Moeller<sup>5</sup>, and Kathryn A. Cunningham<sup>1,2</sup>

<sup>1</sup>Center for Addiction Research University of Texas Medical Branch, Galveston, TX <sup>2</sup>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX

<sup>3</sup>Department of Psychiatry, Yale University, New Haven, CT <sup>4</sup>Chemical Biology Research Branch, National Institute on Drug Abuse, DHHS/NIH/NIDA, Bethesda, Maryland <sup>5</sup>Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, VA

### Abstract

A feature of multiple neuropsychiatric disorders is motor impulsivity. Recent studies have implicated serotonin (5-HT) systems in medial prefrontal cortex (mPFC) in mediating individual differences in motor impulsivity, notably the 5-HT<sub>2A</sub>R receptor (5-HT<sub>2A</sub>R) and 5-HT<sub>2C</sub>R. We investigated the hypothesis that differences in the ratio of 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein expression in mPFC would predict the individual level of motor impulsivity and that the engineered loss of the 5-HT<sub>2C</sub>R would result in high motor impulsivity concomitant with elevated 5-HT<sub>2A</sub>R expression and pharmacological sensitivity to the selective 5-HT<sub>2A</sub>R antagonist M100907. High and low impulsive rats were identified in a 1-choice serial reaction time task. Native protein levels of the 5-HT<sub>2A</sub>R and the 5-HT<sub>2C</sub>R predicted the intensity of motor impulsivity and the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R ratio in mPFC positively correlated with levels of premature responses in individual outbred rats. The possibility that the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R act in concert to control motor impulsivity is supported by the observation that high phenotypic motor impulsivity associated with a diminished mPFC synaptosomal 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein:protein interaction. Knockdown of mPFC 5-HT<sub>2C</sub>R resulted in increased motor impulsivity and triggered a functional disruption of the local 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R balance as evidenced by a compensatory upregulation of 5-HT<sub>2A</sub>R protein expression and a leftward shift in the potency of M100907 to suppress impulsive behavior. We infer that there is an interactive relationship between the mPFC 5-HT<sub>2A</sub>R

**Corresponding Author:** Kathryn A. Cunningham, Ph.D., UTMB Center for Addiction Research, University of Texas Medical Branch, Galveston, Texas 77555-0615, kcunning@utmb.edu, Voice 409-772-9629, FAX 409-747-7050.

#### Author Contributions

N.C.A. and K.A.C. conceptualized the experiments, designed and directed the behavioral, biochemical and pharmacological research, interpreted the results, and wrote the manuscript.

S.J.S. carried out behavioral evaluations.

R. M. S. and R. J. D. created the 5-HT<sub>2C</sub>R shRNA AAV.

L.H.L.F., S.E.S.-J. and F.G.M. were involved in the conception and design of the experiments and edited the manuscript.

K.C.R. synthesized M100907 which was provided under a Material Transfer Agreement.

#### Conflict of Interest

Dr. Cunningham is a consultant for Arena Pharmaceuticals. Dr. Moeller is a consultant for Boehringer-Ingelheim. All other authors declare no conflicts of interest.

and 5-HT<sub>2C</sub>R, and that a 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R imbalance may be a functionally-relevant mechanism underlying motor impulsivity.

### Keywords

1-choice serial reaction time task; 5-HT<sub>2A</sub> receptor; 5-HT<sub>2C</sub> receptor; motor impulsivity; medial prefrontal cortex (mPFC); serotonin (5-HT)

## INTRODUCTION

Impulsivity is a complex, multifaceted personality construct<sup>1</sup> and is recognized as a symptomatic element of multiple neuropsychiatric disorders (e.g., attention deficit/hyperactivity disorder, autism, drug addiction).<sup>2</sup> Motor impulsivity (difficulty in withholding a prepotent motor response) and impulsive choice (preference for small immediate rewards over large delayed rewards) are two primary facets of impulsivity which have been reliably assayed with self-report questionnaires and laboratory measures in humans and animals (for reviews).<sup>1,3</sup> Analyses employing choice serial reaction time (CSRT) tasks in outbred rat strains implicate catecholamine,  $\gamma$ -aminobutyric acid (GABA), glutamate and serotonin (5-HT) systems in corticostriatal circuits in inherent motor impulsivity.<sup>4–10</sup> The 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R) and 5-HT<sub>2C</sub>R are G protein-coupled receptors (GPCR) demonstrated to control motor impulsivity. Systemic administration of selective 5-HT<sub>2A</sub>R antagonists (e.g., M100907)<sup>9,11–14</sup> or selective 5-HT<sub>2C</sub>R agonists (e.g., Ro 60–0175, WAY163909)<sup>11,12,14–17</sup> consistently reduce while the preferential 5-HT<sub>2A</sub>R agonist 2,5-dimethoxy-4-iodoamphetamine (DOI)<sup>9,18–26</sup> or the 5-HT<sub>2C</sub>R antagonist SB242084 enhance motor impulsivity.<sup>12,27</sup> The observation that motor impulsivity was synergistically suppressed by the combination of subthreshold doses of M100907 *plus* WAY163909 raises the possibility that the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R may act in concert to regulate impulsive responding.<sup>15</sup>

The control of motor impulsivity by the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R systems intersects within the medial PFC (mPFC), a critical neurobiological substrate of motor impulsivity.<sup>10,28–31</sup> The mRNA and/or protein for both the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R are found in glutamatergic and GABAergic neurons in the mPFC.<sup>32–36</sup> Localized infusion of DOI into the mPFC enhances<sup>37</sup> while intra-mPFC M100907<sup>38</sup> suppresses premature responding assessed in the 5-CSRT task. The density of 5-HT<sub>2A</sub>R<sup>9</sup> as well as 5-HT<sub>2C</sub>R<sup>6</sup> protein expression in the mPFC predicts premature responses in the 1-CSRT task in outbred rats. High impulsive rats exhibit a greater 5-HT<sub>2A</sub>R-mediated head-twitch response and are more sensitive to the suppressive effects of the selective 5-HT<sub>2A</sub>R antagonist M100907<sup>9</sup> while virally-mediated 5-HT<sub>2C</sub>R knockdown in the mPFC generates elevated premature responses in the 1-CSRT task.<sup>6</sup> Taken together, these data suggest that dysregulation of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R neuronal signaling in the mPFC contributed to high levels of inherent motor impulsivity.

The present study was designed to extend previous findings and investigate the hypothesis that the status and balance of the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R in mPFC constitute neurobiological markers of inherent motor impulsivity in an outbred rodent population. We hypothesized that high impulsive (HI) rats, identified based upon levels of premature

responses in the 1-CSRT task,<sup>6,9,13,15,17</sup> would exhibit a higher ratio of 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R (5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R) expression in the mPFC, along with our previously observed higher and lower levels of 5-HT<sub>2A</sub>R<sup>9</sup> and 5-HT<sub>2C</sub>R,<sup>6</sup> respectively, and a disruption in the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein:protein interaction, relative to low impulsive (LI) rats. Lastly, we tested the hypothesis that the genetic knockdown of 5-HT<sub>2C</sub>R in the mPFC will evoke high motor impulsivity concomitant with elevated 5-HT<sub>2A</sub>R expression and pharmacological sensitivity to the suppressive effects of the selective 5-HT<sub>2A</sub>R antagonist M100907 relative to control rats. The observed differential ratio of native 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R in high vs. low impulsive outbred rats as well as the observations from an engineered imbalance in the 5-HT<sub>2R</sub> system suggest that cortical 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R homeostasis is a key regulatory factor in motor impulsivity.

## RESULTS AND DISCUSSION

### Phenotypic stratification of motor impulsivity is achievable with the 1-CSRT task

The motor impulsivity phenotype is reliably identifiable in CSRT tasks.<sup>4-9</sup> Here, a cohort of outbred rats was stratified for the motor impulsivity phenotype using the 1-CSRT task. High (HI; n=9) and low impulsive rats (LI; n=9) were classified as the upper and lower quartile based upon premature responses on an ITI8 challenge session; the ITI8 challenge promotes premature responding and thus more easily allows for the detection of phenotypic differences.<sup>4-9</sup> Accuracy on the ITI5 during task training and maintenance sessions and on the ITI8 challenge session averaged 97–98% indicating that rats detected the stimuli and performed effectively under both ITI conditions.<sup>6,9</sup> Figure 1A illustrates the ordinal distribution of individual rats plotted by premature responses for the upper (HI) and lower (LI) quartile of rats relative to those in the mid (MI) range (middle two quartiles). HI rats engendered more premature responses vs. LI rats (Fig. 1B;  $p < 0.001$ ). HI rats earned fewer reinforcers (Fig. 1C;  $p < 0.05$ ) and exhibited lower percent omissions (Fig. 1D;  $p < 0.05$ ) vs. LI rats. No differences between LI and HI on ITI8 were observed in accuracy ( $97.3\% \pm 1.3$  vs.  $97.8\% \pm 1.1$ ) or the latency to the first pellet ( $1.6 \pm 0.7$  sec vs.  $0.6 \pm 0.2$ ). There was no significant difference in 1-CSRT task performance or phenotypic identification between the three cohorts of rats (data not shown) employed in the present studies (See Research Design).<sup>6,9</sup> Thus, the natural variation in levels of motor impulsivity in an outbred rat population is quantifiable in the 1-CSRT task.<sup>6,9</sup>

### The mPFC 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R synaptosomal protein profile distinguishes motor impulsivity phenotypes

The 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R regulate the excitatory/inhibitory balance in the mPFC and the net consequence of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R activation on cortical neurons is interactive as shown by the observation that constitutive knockout of the 5-HT<sub>2A</sub>R upregulates 5-HT<sub>2C</sub>R control over the excitability of mPFC pyramidal neurons.<sup>39</sup> Rodent studies provide the opportunity to link individual differences in motor impulsivity with the functional capacity of cortical 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R *ex vivo*. The 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R are detected postsynaptically with a smaller proportion found in the presynaptic milieu in forebrain.<sup>40-42</sup> To assess the available synaptosomal pool of receptors as a possible factor in differential receptor functionality and a neurobiological substrate of inherent motor impulsivity, we

evaluated 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R synaptosomal protein expression in the mPFC in individual HI and LI rats. The synaptosomal protein fraction employed is enriched for the presynaptic and postsynaptic compartments.<sup>43</sup> High impulsive rats (determined from the ITI8 challenge) demonstrated higher synaptosomal mPFC 5-HT<sub>2A</sub>R (Fig. 2A,  $p < 0.05$ )<sup>9</sup> and lower synaptosomal mPFC 5-HT<sub>2C</sub>R (Fig. 2B,  $p < 0.05$ ),<sup>6</sup> resulting in a higher ratio of 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R (5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R; Fig. 2C,  $p < 0.001$ ). Premature responses positively correlated with mPFC 5-HT<sub>2A</sub>R synaptosomal protein levels (Fig. 2D;  $r^2 = 0.373$ ;  $p = 0.027$ ), inversely correlated with mPFC 5-HT<sub>2C</sub>R synaptosomal protein levels (Fig. 2E,  $r^2 = 0.512$ ;  $p = 0.004$ ) and positively correlated with the mPFC 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R ratio (Fig. 2F,  $r^2 = 0.537$ ;  $p = 0.004$ ). In contrast, the reinforcers earned on the ITI8 challenge did not correlate with either 5-HT<sub>2A</sub>R ( $r^2 = 0.0647$ ;  $p = 0.380$ ) or 5-HT<sub>2C</sub>R ( $r^2 = 0.0684$ ;  $p = 0.367$ ) protein expression in mPFC; a trend toward a correlation between reinforcers earned and the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R ratio was seen ( $r^2 = 0.252$ ;  $p = 0.067$ ). The percent omissions positively correlated with 5-HT<sub>2C</sub>R ( $r^2 = 0.647$ ;  $p < 0.001$ ) and inversely correlated with the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R ratio ( $r^2 = 0.484$ ;  $p = 0.006$ ), but not with 5-HT<sub>2A</sub>R expression ( $r^2 = 0.101$ ;  $p = 0.267$ ). Taken together, these data indicate that the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R balance is a neurobiological substrate underlying both prepotent responding and motivational drive in high inherent motor impulsivity.

### High motor impulsivity associates with lower 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein complex formation in the mPFC

The 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R transcript and/or protein have been localized to both glutamate and GABA neurons in the mPFC,<sup>32–35,44–47</sup> and has most recently been found to colocalize in GABA neurons, and perhaps pyramidal neurons of the mPFC.<sup>36</sup> Given the association of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R proteins in mPFC with levels of motor impulsivity (Fig. 2),<sup>6,9</sup> we further considered the possibility that a 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein complex may exist in the mPFC and that the pattern of complex formation may track with inherent motor impulsivity. Co-immunoprecipitation protocols<sup>6,9,17,40</sup> were employed to assess the protein:protein interaction of the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R in the mPFC. This technique is based on the ability of an antibody to capture the primary target (e.g., 5-HT<sub>2A</sub>R or 5-HT<sub>2C</sub>R) as well as other macromolecules that are bound to the target within a tissue lysate (in this case, mPFC crude synaptosomal protein). The co-immunoprecipitation assay was conducted under saturating antibody conditions, but not 100% efficiency, to control for the expression differences in 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R in HI vs. LI rats. We immunoprecipitated comparable amounts (~5 µg) of 5-HT<sub>2A</sub>R or 5-HT<sub>2C</sub>R from mPFC synaptosomal protein extracts of HI and LI rats and then equal amounts of protein (1 µg) were subjected to immunoblot analyses for the receptor (performed in duplicate) (Fig. 3). Immunoprecipitation (IP) of synaptosomal protein extracts of the mPFC using the 5-HT<sub>2C</sub>R antibody followed by immunoblot (IB) with the 5-HT<sub>2A</sub>R antibody yielded a band at the expected molecular weight (~55 kDa) for 5-HT<sub>2A</sub>R (Fig. 3A); the reciprocal experiment (5-HT<sub>2A</sub>R IP followed by 5-HT<sub>2C</sub>R IB) yielded a band at the expected molecular weight (~46 kDa) for 5-HT<sub>2C</sub>R (Fig. 3B). Intriguingly, the synaptosomal 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein interaction was attenuated in the mPFC of HI relative to LI rats (Figs. 3A and 3B,  $p < 0.05$ ), suggesting that a 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R complex exists and may be poised to confer regulatory control over the mPFC

microcircuitry and output important in inherent motor impulsivity via actions at the single neuron level.

### Engineered loss of 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R balance confers high motor impulsivity

We next tested the hypothesis that, if the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R homeostasis in mPFC is important in the control of motor impulsivity, then loss of the 5-HT<sub>2C</sub>R in this region would tilt the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R balance towards a greater 5-HT<sub>2A</sub>R influence. In the present experiment, we targeted the mPFC comprising the ventral prelimbic and dorsal infralimbic subnuclei<sup>6</sup> and employed adeno-associated viral (AAV) vectors to selectively suppress expression of the 5-HT<sub>2C</sub>R using RNA interference to silence gene expression and to curtail production of the protein. Details of the shRNA design, production and validation of the AAV vectors are published.<sup>6</sup> The *ex vivo* analyses of microinfusion placements in individual rats illustrated that the viral infection was localized within the mPFC along the boundary of the ventral prelimbic/dorsal infralimbic subnuclei (data not shown). The mPFC of a rat infused with the non-silencing control (NSC)-eGFP AAV exhibited 5-HT<sub>2C</sub>R-immunoreactivity in infected neurons (yellow arrows) and non-infected neurons (white arrows; Fig. 4A, left) while that of a rat infused with the 5-HT<sub>2C</sub>R shRNA-eGFP AAV exhibited reduced 5-HT<sub>2C</sub>R-immunoreactivity in infected neurons (yellow arrows) relative to non-infected neurons (white arrows; Fig. 4A, right).

*Ex vivo* analyses indicated that the 5-HT<sub>2C</sub>R shRNA-eGFP AAV significantly attenuated 5-HT<sub>2C</sub>R protein expression (Fig. 4B,  $p < 0.05$ ) and augmented 5-HT<sub>2A</sub>R protein expression (Fig. 4C,  $p < 0.05$ ) relative to control rats. Rats with a knockdown of the 5-HT<sub>2C</sub>R in the mPFC expressed significantly higher premature responses on both ITI5 maintenance and ITI8 challenge sessions relative to control rats infused with the NSC-eGFP AAV (Fig. 4D,  $p < 0.05$ ). The accuracy in control vs. 5-HT<sub>2C</sub>R knockdown rats on the ITI5 maintenance ( $96.3\% \pm 0.7$  vs.  $97.5\% \pm 0.2$ ) and ITI8 challenge sessions ( $97.6\% \pm 0.8$  vs.  $98.3\% \pm 0.7$ ) did not differ nor did the latency to start the ITI5 ( $1.3 \pm 0.3$  sec vs.  $1.1 \pm 0.3$  sec) or ITI8 ( $0.7 \pm 0.3$  sec vs.  $1.3 \pm 0.5$  sec) sessions. Control vs. 5-HT<sub>2C</sub>R knockdown rats also did not differ in the number of reinforcers earned (Fig. 4E, n.s.). There was a significant decrease in percent omissions between control and knockdown rats on both the ITI5 and ITI8 challenge sessions (Fig. 4F,  $p < 0.05$ ). These data indicate a role of the mPFC 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R balance to selectively govern premature and motivational responding, key facets underlying motor impulsivity in the 1-CSRT task.<sup>6</sup>

Systemic administration of a selective 5-HT<sub>2A</sub>R antagonist attenuates motor impulsivity in the 1- or 5-CSRT tasks.<sup>11–13,15,24,48</sup> HI rats demonstrated higher levels of mPFC 5-HT<sub>2A</sub>R protein levels (replicated here; Fig. 2A) and higher pharmacological sensitivity to the selective 5-HT<sub>2A</sub>R antagonist M100907.<sup>9</sup> Thus, we tested the hypothesis that the engineered imbalance in 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R (Figs. 4B and 4C) would associate with a leftward shift in the potency of M100907 to suppress motor impulsivity. The dose range of M100907 (0.001–0.1 mg/kg) and time of injection (30 min prior) were chosen based upon the protocols employed to demonstrate that high impulsive outbred Sprague-Dawley rats were more sensitive to the behavioral effects of M100907.<sup>9</sup> Vehicle-treated 5-HT<sub>2C</sub>R shRNA-eGFP AAV rats demonstrated elevated premature responses relative to vehicle-treated NSC-eGFP

AAV rats (Fig. 5A;  $p < 0.05$ ), as demonstrated previously.<sup>6</sup> M100907 dose-dependently decreased premature responses; there was no main effect of pretreatment (NSC-eGFP AAV, 5-HT<sub>2C</sub>R shRNA-eGFP AAV) on premature responses ( $F_{1,68} = 0.05$ , n.s.), but a main effect of treatment (M100907 doses) ( $F_{3,68} = 13.82$ ,  $p < 0.001$ ) and a pretreatment X treatment interaction ( $F_{3,68} = 3.07$ ,  $p < 0.05$ ) were observed. In 5-HT<sub>2C</sub>R knockdown rats, a main effect of M100907 treatment was observed ( $F_{3,37} = 15.56$ ,  $p < 0.001$ ); planned comparisons showed that both the 0.01 and 0.1 mg/kg doses of M100907 decreased premature responses *vs.* vehicle in knockdown rats. In control rats, a trend towards a main effect of M100907 treatment was observed ( $F_{3,30} = 2.78$ ,  $p = 0.06$ ). Hence, the decrement in 5-HT<sub>2C</sub>R following infusion of the 5-HT<sub>2C</sub>R-shRNA-AAV into the mPFC enhances 5-HT<sub>2A</sub>R control over motor impulsivity.

The number of reinforcers earned increased significantly in 5-HT<sub>2C</sub>R knockdown, but not control, rats administered M100907 (Fig. 5B), an effect similarly noted in HI rats.<sup>9</sup> No main effect of pretreatment ( $F_{1,68} = 0.05$ , n.s.), a main effect of treatment ( $F_{3,68} = 9.07$ , n.s.), but no pretreatment X treatment interaction ( $F_{3,68} = 2.08$ , n.s.) on reinforcers earned was observed. In 5-HT<sub>2C</sub>R knockdown rats, a main effect of M100907 treatment on reinforcers earned was observed ( $F_{3,30} = 6.56$ , n.s.); 0.01 and 0.1 mg/kg of M100907 significantly increased reinforcers earned in knockdown rats. In control rats, a main effect of M100907 treatment on reinforcers earned was not observed ( $F_{3,30} = 0.42$ , n.s.). No main effect of pretreatment ( $F_{1,68} = 0.64$ , n.s.), no main effect of treatment ( $F_{3,68} = 0.61$ , n.s.), and no pretreatment X treatment interaction ( $F_{3,68} = 1.20$ , n.s.) on percent omissions were observed (Fig. 5C). These findings suggest that M100907 may selectively enhance cognition under conditions in which the impulse control system is taxed.<sup>9,49,50</sup>

Components of motor impulsivity as a cognitive construct include, but are not limited to, inhibitory control, failure to consider the consequences of behavior, a sense of urgency prior to or during task performance, and the attraction to approach and attain rewards (incentive motivation; 'wanting').<sup>1,51,52</sup> At both molecular and systems levels, the brain utilizes 5-HT within cellular cascades and webs comprised of transcription factors, growth factors and other neurotransmitters, as a mediator of integral physiological and psychological functions, including the processing of incentive-motivational stimuli and impulse control.<sup>51,53–56</sup> Acute tryptophan depletion in humans, which temporarily lowers brain 5-HT levels, elevates motor impulsivity<sup>57</sup> and disrupts motivated actions selectively in individuals with high inherent impulsivity.<sup>58</sup> Depletion of 5-HT in the dorsal raphe nucleus causes a robust increase in impulsive action in rodents,<sup>59,60</sup> while elevated 5-HT release in the mPFC positively correlates with motor impulsivity.<sup>61,62</sup> The conflicting outcomes from global 5-HT manipulations highlight not only the multidimensionality of impulsivity, but also that the ultimate impact of 5-HT is governed by its actions at 5-HT receptor proteins, including the 5-HT<sub>2R</sub> family.

The engagement of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R mechanisms in the control of motor impulsivity (for review)<sup>31</sup> is further supported by the results of the present study. We discovered that high impulsive rats (both inherent and engineered) displayed enhanced prepotent responding and motivationally-driven behavior (as evidenced by greater premature responses and fewer omissions made, respectively). Further, motor impulsivity (premature responses) and

motivation to respond (omissions) associated with the ratio of 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R protein expression in the mPFC. The mechanisms that generate a specific receptor protein profile that associates with an expressed behavioral phenotype are currently unknown. Given that the expression of 5-HT receptors in human PFC appears to remain balanced across development into adulthood<sup>63</sup> and that early life events are known to trigger plasticity of 5-HT systems,<sup>64–66</sup> it is possible that differential developmental experience<sup>67</sup> could have durable ramifications for 5-HT receptor control of the mPFC microcircuitry. This hypothesis remains to be tested, however, a functional 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R rheostat in mPFC may play a pivotal role in spontaneously-occurring individual differences in impulsivity.

Phenotypic variance in motor impulsivity has been linked to several candidate neurotransmitter mechanisms within limbic-corticostriatal circuitry.<sup>68</sup> We propose that vulnerability to motor impulsivity associates with expression patterns of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R (present study),<sup>6,7,9</sup> while multiple studies implicate dopamine<sup>5,7,69</sup>,  $\gamma$ -aminobutyric acid (GABA)<sup>8,10</sup> and glutamate system involvement.<sup>37,70–73</sup> Our observation that knockdown of the mPFC 5-HT<sub>2C</sub>R does not fully recapitulate the motor impulsivity phenotype characterized in outbred rats suggests an interplay between serotonergic and other neurochemical circuits may be differentially recruited in the expression of distinct components of impulsive behavior. One candidate mechanism is the interaction between 5-HT and glutamate systems in the mPFC. Pretreatment with a glutamate mGlu2/3 receptor agonists has been shown to suppress motor impulsivity generated by excessive 5-HT<sub>2A</sub>R stimulation locally in the mPFC,<sup>37</sup> presumably due to the actions of mGlu2/3 agonists to suppress 5-HT<sub>2A</sub>R-mediated glutamate release from neurons that terminate onto mPFC pyramidal cells.<sup>74</sup> Thus, the differential recruitment of a “functional crosstalk” between the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R (present results), the mGlu2/3 and 5-HT<sub>2A</sub>R,<sup>37</sup> or other combinations of receptors may be critical drivers of the phenotypic profile of impulsivity.

A higher ratio of the 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R protein density in frontal cortex has been noted for the mouse, rat and human,<sup>75</sup> and here we report that the ratio of 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R protein expression in the rat mPFC predicts the inherent level of motor impulsivity in individual rats. That the net consequence of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R function in mPFC may be reciprocal or interactive is supported by the present finding that knockdown of 5-HT<sub>2C</sub>R in the mPFC increased motor impulsivity and resulted in a compensatory upregulation of 5-HT<sub>2A</sub>R protein expression and a leftward shift in the potency of M100907 to suppress impulsive behavior. These findings are consistent with a study which suggested that the constitutive knockout of the 5-HT<sub>2A</sub>R upregulated 5-HT<sub>2C</sub>R control over the excitability of mPFC pyramidal neurons.<sup>39</sup> Further, signal transduction through the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R locally controls the intrinsic microcircuitry of the PFC through postsynaptic modulation of synaptic input to pyramidal neurons and subpopulations of interneurons (for review)<sup>76</sup> and potentially via regulation of neurotransmitter release (e.g., acetylcholine, dopamine) by presynaptic 5-HT<sub>2A</sub>R and/or 5-HT<sub>2C</sub>R heteroreceptors (for review).<sup>77</sup>

Our finding that these two GPCRs reside in the same protein complex and that this complex is enriched in the mPFC of low impulsive rats suggests that the behavioral output of the mPFC is dependent in part upon a 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein:protein interaction. Our unpublished data corroborates a recent publication<sup>36</sup> which demonstrated that the majority

of GABA neurons in the prelimbic mPFC expressed 5-HT<sub>2C</sub>R immunoreactivity and most co-expressed 5-HT<sub>2A</sub>R immunoreactivity; a small population of cells with a pyramidal profile also expressed both receptors. The colocalization of the receptors in the same neuron suggests that the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein complex may occur at the single cell level. Serotonin actions at the 5-HT<sub>2A</sub>R are excitatory in both interneurons and pyramidal neurons of the neocortex (for review),<sup>76</sup> with these actions noted to be activity-dependent<sup>78</sup> and projection-specific.<sup>79</sup> There is much less known, and some debate, concerning the modulatory actions of 5-HT at the 5-HT<sub>2C</sub>R in cortical neurons.<sup>80</sup> Activation of 5-HT<sub>2C</sub>R depolarized pyramidal neurons in piriform cortex<sup>81</sup> however, the observed 5-HT-induced depolarization of mPFC pyramidal neurons is not blocked by the selective 5-HT<sub>2C</sub>R antagonist SB242084.<sup>39,82</sup> The complexity of the mPFC functional microcircuitry modulated by 5-HT via the 5-HT<sub>2R</sub> may be founded in the different subpopulations of interneurons which express the receptors (e.g., parvalbumin, calbindin, calretinin).<sup>46,83</sup> Further, the impact of a 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein complex on neuronal firing is not known and it is wholly possible that the biochemical, signaling, and pharmacological properties of the protein complex diverge from that of the single receptor, although this is a controversial and active research topic.<sup>84–87</sup> Thus, while future research is required to tease apart the relative role of these two GPCRs within the same neurons versus interacting neurons in the mPFC, altered firing of GABA neurons which colocalize the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R may dysregulate pyramidal outflow to drive motor impulsivity. The fact that systemic administration of 5-HT<sub>2A</sub>R and the 5-HT<sub>2C</sub>R ligands oppositionally control motor impulsivity<sup>9,11–20,22–26</sup> (and other behaviors)<sup>88</sup> adds further impetus to disentangling the mechanisms through which these receptors control neuronal output to mediate behaviors that contribute to chronic health disorders (e.g., drug addiction, attention deficit disorder, autism, and obesity/binge eating disorder).

## METHODS

### General Methods

**Animals**—Male, outbred Sprague–Dawley rats (n=120); Harlan, Houston, TX) weighing 250–275g upon arrival were housed two/cage under a 12-h light–dark cycle with controlled temperature (21–23°C) and humidity (40–50%). Animals were acclimated for seven days to the colony room prior to the start of handling and experimental procedures. During the 1-CSRT task acquisition and maintenance, rats were food restricted to 90% free-feeding weight; water was available *ad libitum* except during daily operant sessions. Rats were weighed daily to ensure that their body weights were maintained at 90% of free-feeding levels. All experiments were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (2011) and with the University of Texas Medical Branch Institutional Animal Care and Use Committee approval.

**Drugs**—M100907 [*R*-(1)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol] was synthesized by Kenner Rice (National Institute on Drug Abuse, Bethesda, MD) and dissolved in 1% Tween 80 in 0.9% NaCl.



**1-Choice Serial Reaction Time (1-CSRT) task**—Procedures occurred in standard five-hole nose-poke operant chambers equipped with a houselight, food tray, and an external pellet dispenser capable of delivering 45 mg pellets (Bio-Serv, Frenchtown, NJ) housed within ventilated and sound-attenuated chambers (MedAssociates, St Albans, VT). The 1-CSRT task methodology has been described in detail previously.<sup>6,9,13,15,17</sup> Briefly, rats were habituated to the test chamber; a nose-poke into the singly-illuminated center hole resulted in the delivery of one food pellet into the magazine on the opposite wall of the chamber and simultaneous illumination of the magazine light. During this stage, all responses made in the correctly lit (center) hole resulted in the illumination of the magazine light and presentation of a single food pellet. The training stages thereafter were each comprised of daily sessions of 100 trials to be completed in a maximum of 30 min; each training stage (9 total) involved incrementally lowering the stimulus duration with a 5-sec limited hold and an intertrial interval (ITI) of 5 sec. A maximum of 100 correct responses in a session resulted in a maximum of 100 reinforcers earned; incorrect, premature responses or omissions resulted in a 5-s time-out period and a reduction in reinforcers obtained. Advancement to the next training stage required rats to meet acquisition criteria: 50 correct responses, >80% accuracy [correct responses/(correct + incorrect) × 100] and <20% omissions (omitted responses/trials completed × 100).<sup>13</sup> Premature responses were employed as the primary indication of motor impulsivity. The number of reinforcers earned provides a measure of task competency and a secondary assessment of motor impulsivity, while percent accuracy was a general indication of attentional capacity. Percent omissions indicated failures of detection of the visual stimuli in the center hole as well as motivation to perform the task.

**Identification of motor impulsivity phenotype**—After meeting stability criteria for the final training stage over three consecutive ITI5 sessions (with <20% variability, approximately days 25–30), an ITI8 challenge session was conducted in which the ITI was 8-s for the session.<sup>6,9,61</sup> High and low impulsive rats were defined as the upper and lower quartile of premature responses assessed on the ITI8 challenge, respectively.

## Research Design

***Inherent motor impulsivity predicts expression patterns of 5-HT<sub>2A</sub>R to 5-HT<sub>2C</sub>R protein in mPFC in individual rats (see experimental timeline; Fig. 2)***—HI and LI rats were identified from three independent cohorts of outbred rats (Cohort 1: 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R expression and ratio; Cohorts 2 and 3: 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein complex). Two to three days following behavioral testing, rats were anesthetized [chloral hydrate solution (400 mg/kg)], decapitated and brains were extracted. The mPFC (containing infralimbic, prelimbic and anterior cingulate cortex) was microdissected immediately over ice, flash frozen in liquid nitrogen and stored at –80°C for subsequent protein extraction.

A crude synaptosomal protein fraction enriched for pre- and postsynaptic proteins (i.e., presynaptic terminals, postsynaptic membranes, postsynaptic density, synaptic protein complexes) was prepared as described previously.<sup>40,83</sup> Tissue from the mPFC was homogenized in 10 times w/v ice cold Krebs buffer (125 mM NaCl, 1.2 mM KCl, 1.2 mM MgSO<sub>4</sub>, 1.2 mM CaCl<sub>2</sub>, 22 mM Na<sub>2</sub>CO<sub>3</sub>, 1 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM glucose) containing 0.32

M sucrose plus protease inhibitor cocktail and phosphatase inhibitor 2 and 3 cocktails (10  $\mu\text{L}/\text{mL}$ ; Sigma-Aldrich, St. Louis, MO). The homogenate was centrifuged at 1000 g for 10 min at 4°C to pellet the nuclear fraction. The supernatant was collected and centrifuged at 16,000 g for 20 min at 4°C to pellet the crude synaptosome. The pellet was re-suspended in Krebs buffer with 1% dodecyl maltoside.

Equal amounts of crude synaptosomal protein prepared from the mPFC<sup>6,9,40</sup> were separated by SDS-PAGE and transferred to a PVDF membrane for blotting with 5-HT<sub>2A</sub>R antibody (AB16028, 1:1000; Abcam, Cambridge, MA), 5-HT<sub>2C</sub>R antibody (D12, 1:100; Santa Cruz Biotechnology, Dallas, TX) or pan-cadherin antibody (AB6528, 1:10000; Abcam). Membranes were incubated with mouse IgG IRDye 800 (1:10000) or rabbit IgG IRDye 680 (1:10000) for detection by Odyssey Imaging System (LI-COR, Lincoln, NE). The integrated intensity of each band was analyzed with the Odyssey Software and 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R immunoreactivity normalized to pan-cadherin immunoreactivity.

Co-immunoprecipitation methodology was employed to assess the 5-HT<sub>2C</sub>R protein complex with 5-HT<sub>2A</sub>R in the mPFC of HI and LI rats (n=4–5/phenotype). The 5-HT<sub>2C</sub>R antibody (D12, 45  $\mu\text{g}$ , Santa Cruz) or 5-HT<sub>2A</sub>R antibody (AB16028, 10  $\mu\text{g}$ , Abcam) was covalently crosslinked onto protein A/G resin as previously described with minor modifications.<sup>9,40</sup> Synaptosomal protein was incubated with the antibody-crosslinked resin for 48 hrs at 4°C with constant shaking. The eluted protein was resuspended in resuspension buffer containing 1% SDS and 0.5% NP40 and subjected to the Wes™ automated western blotting system (ProteinSimple, San Jose, CA [www.proteinsimple.com/](http://www.proteinsimple.com/)), which utilizes capillary electrophoresis-based immunodetection for higher resolution, sensitivity, and reproducibility (even at low sample concentrations) relative to traditional immunoblotting techniques.<sup>9,89</sup> Wes™ reagents (biotinylated molecular weight marker, streptavidin-HRP fluorescent standards, luminol-S, hydrogen peroxide, sample buffer, DTT, stacking matrix, separation matrix, running buffer, wash buffer, matrix removal buffer, secondary antibodies, antibody diluent, and capillaries) were obtained from the manufacturer (ProteinSimple) and used according to the manufacturer's recommendations. The 5-HT<sub>2A</sub>R antibody (AB16028, 1:250) or 5-HT<sub>2C</sub>R antibody (D12, 1:50; Santa Cruz) was diluted with ProteinSimple antibody diluent.

Equal amounts of protein (1  $\mu\text{g}$ ) were combined with 0.1X sample buffer and 5X master mix (200 mM DTT, 5X sample buffer, 5X fluorescent standards), gently mixed, and then denatured at 95°C for 5 min. The denatured samples, biotinylated ladder, antibody diluent, primary antibodies, HRP-conjugated secondary antibodies, chemiluminescent substrate, and wash buffer were dispensed to designated wells in a pre-filled microplate (ProteinSimple). Separation electrophoresis (375 V, 31 min, 25°C) and immunodetection in the capillaries were fully automated using the following settings: separation matrix load for 200-s, stacking matrix load for 14-s, sample load for 7-s, antibody diluent for 30 min, primary antibody incubation for 60 min, secondary antibody incubation for 30 min, and chemiluminescent signal exposure for 30-s, 120-s, 240-s, and 480-s. Data analyses were performed using the Compass Software (ProteinSimple).

**Genetic loss of mPFC 5-HT<sub>2C</sub>R confers high motor impulsivity and an imbalance in the 5-HT<sub>2R</sub> system (see experimental timeline, Fig. 4)**—A 24-nucleotide sequence within the coding region of the *Htr2c* was identified employing methods we have previously reported.<sup>90</sup> Two sets of oligonucleotides (Integrated DNA Technology, Coralville, IA) for cloning were synthesized [*Htr2c* shRNA (top, 5'-TTGAATCCAGACGGGGCACAAATATCCTTCTGTCAGATATTTGTGCCCCGTCTG GATTATTTTT-3'; bottom, 5'-CTAGAAAATAATCCAGACGGGGCACAAATATCTGACAGGAAGGATATT TGTGCCCCGTCTGGATTC-3'); Non-silencing control (NSC) shRNA (top, 5'-TTTGTGGAGCCGAGTTTCTAAATTCGGCTTCTGTCACGGAATTTAGAAAACCCGG CTCCAATTTTT-3'; bottom, 5'-CTAGAAAATTGGAGCCGGGTTTCTAAATTCCGTGACA GGAAGCGGAATTTAGAAACTCGGCTCCAC3')]. Oligonucleotides were designed with SapI and XbaI overhangs to allow ligation downstream of the mU6pro region of a modified pAAV-MCS vector, pAAV-shRNA, which was designed to coexpress hairpin RNAs, under the control of a mU6pro and an SV40 polyadenylation site, as well as eGFP controlled by an independent CMV promoter and hGH polyadenylation sequence. Adeno-associated viral (AAV) serotype type 2 vectors were packaged using a helper-free packaging system (Life Technologies) and purified viral stocks were assayed in camptothecin-treated HT1080 cells to confirm titers of  $1-2 \times 10^{11}$  transducing units/ml.

Rats (n=24) were anesthetized (i.m.) with a cocktail containing xylazine (8.6 mg/kg), acepromazine (1.5 mg/kg), and ketamine (43 mg/kg) in bacteriostatic saline and placed in a stereotaxic apparatus with the upper incisor bar at -3.8 mm below the interaural line. Two microsyringes (28 gauge, Hamilton Company, Reno, NV) were lowered bilaterally at 15° from the midsagittal plane relative to bregma<sup>91</sup> to target the mPFC encompassing the ventral prelimbic and dorsal infralimbic subnuclei;<sup>6</sup> the coordinates were anteroposterior +3mm, mediolateral +1.8mm, and dorsoventral -5.1mm from the skull. The NSC shRNA-eGFP AAV ("control"; 1.5 µl) or 5-HT<sub>2C</sub>R shRNA-eGFP ("5-HT<sub>2C</sub>R knockdown"; 1.5 µl) AAV vectors were infused bilaterally at 0.1 µl/min over 15 min. Rats were allowed three weeks to recover and allow for stable transgene expression prior to behavioral assessment. AAV infection has been well-characterized with stabilization of gene expression in rodent brain at three weeks and with stability for at least 12–18 months post-infection.<sup>92, 93</sup>

Following intra-mPFC transgene delivery and stable viral vector expression,<sup>6</sup> control (n=12) and 5-HT<sub>2C</sub>R knockdown (n=12) rats were trained to criteria on the 1-CSRT task. Pharmacological test sessions commenced after animals met the stable training criteria >80% accuracy and <20% omissions for five consecutive training sessions on the final training stage with less than 15% variability across sessions;<sup>9,15,17</sup> vehicle (1% Tween80; i.p.) or M100907 (0.001, 0.01, 0.1 mg/kg; i.p.) was injected 30 min prior to commencement of 1-CSRT task sessions under ITI5 conditions. Each rat received all doses of M100907 in a balanced, pseudo-randomized order. Rats underwent five daily 1-CSRT task sessions per week; rats were treated with vehicle the day before drug treatments and received only one drug treatment per week.

At the termination of the pharmacological assessments (~1 week), rats were anesthetized (chloral hydrate; 400 mg/kg, i.p.), decapitated and tissue extracted for visualization and 5-HT<sub>2</sub>R capillary electrophoretic immunoblot analyses.<sup>6</sup> A 1-mm coronal section containing the mPFC was placed on a cold glass slide and rapid visualization of eGFP *ex vivo* was accomplished with a DFP-1 Dual Fluorescent Protein Flashlight by the investigator wearing a pair of VG2 barrier filter glasses (Nightsea, Bedford, MA, USA).<sup>6,94</sup> Photomicrographs of coronal sections were taken with a DSLR camera equipped with a macro lens and yellow filter.<sup>6,94</sup> Fluorescent and non-fluorescent regions from the mPFC were microdissected and assayed for immunoblotting to assess 5-HT<sub>2C</sub>R knockdown and 5-HT<sub>2A</sub>R protein levels *ex vivo*.<sup>6,94</sup> The S2 protein fraction (i.e., soluble protein; see above) was modified by the addition of 0.5% NP40. The 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R protein levels were assessed using the Wes™ automated western blotting system (ProteinSimple) as described above. Data analyses were performed using the Compass Software (ProteinSimple).

A subset of rats (n=6) was anesthetized (sodium pentobarbital; 100 mg/kg, i.p.) and perfused transcardially with 3% paraformaldehyde for immunohistochemical analyses.<sup>695</sup> Brains were removed, post-fixed (2 hrs) and cryoprotected in 30% sucrose solution. Free-floating coronal sections at the level of the mPFC (30 μm) were incubated in 0.5% sodium borohydride to reduce autofluorescence. Sections were blocked (1.5% normal goat serum in 0.4% triton-PBS) prior to incubation with 5-HT<sub>2C</sub>R antibody (D12; 1:100; Santa Cruz; 2 hrs 25°C, 18 hr 4°C) followed by AlexaFluor 555 to mouse IgG (A21424, 1:2000; Life Technologies; 1 hr 25°C). Slides were coverslipped with Vectashield fluorescent mounting medium with DAPI (Vector Laboratories, Burlingame, CA).

**Statistical Analyses**—Student's *t*-test was employed to analyze outcome measures of 1-CSRT task performance between cohorts, phenotypes or pretreatment groups. The 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R protein expression data and the ratio were assessed by Student's *t*-test and Pearson's correlation. The effects of M100907 on 1-CSRT task performance in control and knockdown rats were analyzed by two-way repeated-measures ANOVA for the factors of pretreatment (control or knockdown) and treatment (vehicle or M100907); the effects of treatment were assessed by one-way repeated-measures ANOVA followed by Dunnett's procedure (for comparisons of treatment means *vs.* vehicle). The experimenter was blinded to the group allocation (e.g., HI *vs.* LI; control *vs.* knockdown) throughout the duration of the study. Analyses were performed in SAS (version 9.4; Cary, NC) with an experiment-wise error rate of  $\alpha=0.05$ .

## Acknowledgments

This work was supported by NIDA grants K99 DA033374 (N.C.A.), F30 DA034488 (L.H.L.F.), F31 DA035620 (S.E.S.-J.), T32 DA07287 (L.H.L.F. and S.E.S.-J.), P20 DA024157 (K.A.C.), P50 DA033935 (K.A.C.), K05 DA020087 (K.A.C.), and the Center for Addiction Research at the University of Texas Medical Branch. The research was also supported by the NIH Intramural Research Programs in the Drug Design and Synthesis Section of the Chemical Biology Research Branch within the National Institutes of Health Intramural Research Programs of the National Institute on Drug Abuse (NIDA) and the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (K.C.R.). We would like to thank Mr. Siddharth Iyengar and Ms. Justine Saavedra for technical assistance with *ex vivo* biochemical analyses.

## Abbreviations

<b>1-CSRT</b>	one-choice serial reaction time task
<b>5-HT</b>	serotonin (5-hydroxytryptamine)
<b>5-HT<sub>X</sub>R</b>	5-HT <sub>X</sub> receptor
<b>GPCR</b>	G-protein coupled receptor
<b>AAV</b>	adenoassociated virus

## REFERENCES

1. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. *Am.J.Psychiatry.* 2001; 158:1783–1793. [PubMed: 11691682]
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-5. 5th. Arlington, VA: American Psychiatric Publishing; 2013.
3. Weafer J, Baggott MJ, de Wit H. Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention. *Exp Clin Psychopharmacol.* 2013; 21:475–481. [PubMed: 24099351]
4. Economidou D, Theobald DE, Robbins TW, Everitt BJ, Dalley JW. Norepinephrine and dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleus accumbens. *Neuropsychopharmacology.* 2012; 37:2057–2066. [PubMed: 22510726]
5. Dalley JW, Fryer TD, Brichard L, Robinson ES, Theobald DE, Laane K, Pena Y, Murphy ER, Shah Y, Probst K, Abakumova I, Aigbirhio FI, Richards HK, Hong Y, Baron JC, Everitt BJ, Robbins TW. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. *Science.* 2007; 315:1267–1270. [PubMed: 17332411]
6. Anastasio NC, Stutz SJ, Fox RG, Sears RM, Emeson RB, DiLeone RJ, O'Neil RT, Fink LH, Li D, Green TA, Moeller FG, Cunningham KA. Functional status of the serotonin 5-HT<sub>2C</sub> receptor (5-HT<sub>2C</sub>R) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. *Neuropsychopharmacology.* 2014; 39:370–382. [PubMed: 23939424]
7. Besson M, Pelloux Y, Dilleen R, Theobald DE, Lyon A, Belin-Rauscent A, Robbins TW, Dalley JW, Everitt BJ, Belin D. Cocaine modulation of frontostriatal expression of Zif268, D2, and 5-HT<sub>2c</sub> receptors in high and low impulsive rats. *Neuropsychopharmacology.* 2013; 38:1963–1973. [PubMed: 23632436]
8. Caprioli D, Sawiak SJ, Merlo E, Theobald DE, Spoelder M, Jupp B, Voon V, Carpenter TA, Everitt BJ, Robbins TW, Dalley JW. Gamma aminobutyric acidergic and neuronal structural markers in the nucleus accumbens core underlie trait-like impulsive behavior. *Biol Psychiatry.* 2014; 75:115–123. [PubMed: 23973096]
9. Fink LHLANC, Fox RG, Rice KC, Moeller FG, Cunningham KA. Individual differences in impulsive action reflect variation in the cortical serotonin 5-HT<sub>2A</sub> receptor system. *Neuropsychopharmacol.* 2015 in press.
10. Murphy ER, Fernando AB, Urcelay GP, Robinson ES, Mar AC, Theobald DE, Dalley JW, Robbins TW. Impulsive behaviour induced by both NMDA receptor antagonism and GABAA receptor activation in rat ventromedial prefrontal cortex. *Psychopharmacology (Berl).* 2012; 219:401–410. [PubMed: 22101355]
11. Fletcher PJ, Tampakeras M, Sinyard J, Higgins GA. Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. *Psychopharmacology (Berl).* 2007; 195:223–234. [PubMed: 17673981]
12. Winstanley CA, Theobald DE, Dalley JW, Glennon JC, Robbins TW. 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. *Psychopharmacology (Berl).* 2004; 176:376–385. [PubMed: 15232674]

13. Anastasio NC, Stoffel EC, Fox RG, Bubar MJ, Rice KC, Moeller FG, Cunningham KA. Serotonin (5-hydroxytryptamine) 5-HT<sub>2A</sub> receptor: Association with inherent and cocaine-evoked behavioral disinhibition in rats. *Behav.Pharmacol.* 2011; 22:248–261. [PubMed: 21499079]
14. Fletcher PJ, Rizos Z, Noble K, Higgins GA. Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade. *Neuropharmacology.* 2011; 61:468–477. [PubMed: 21402085]
15. Cunningham KA, Anastasio NC, Fox RG, Stutz SJ, Bubar MJ, Swinford SE, Watson CS, Gilbertson SR, Rice KC, Rosenzweig-Lipson S, Moeller FG. Synergism between a serotonin 5-HT<sub>2A</sub> receptor (5-HT<sub>2AR</sub>) antagonist and 5-HT<sub>2CR</sub> agonist suggests new pharmacotherapeutics for cocaine addiction. *ACS Chemical Neuroscience.* 2013; 4:110–121. [PubMed: 23336050]
16. Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M. The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. *Behav.Brain Res.* 2008; 188:412–415. [PubMed: 18191235]
17. Anastasio NC, Gilbertson SR, Bubar MJ, Agarkov A, Stutz SJ, Jeng YJ, Bremer NM, Smith TD, Fox RG, Swinford SE, Seitz PK, Charendoff MN, Craft JW, Laezza F, Watson CS, Briggs JM, Cunningham KA. Peptide inhibitors disrupt the serotonin 5-HT<sub>2C</sub> receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior. *Journal of Neuroscience.* 2013; 33:1615–1630. [PubMed: 23345234]
18. Evenden JL. The pharmacology of impulsive behaviour in rats VII: the effects of serotonergic agonists and antagonists on responding under a discrimination task using unreliable visual stimuli. *Psychopharmacology (Berl).* 1999; 146:422–431. [PubMed: 10550492]
19. Evenden JL, Ryan CN. The pharmacology of impulsive behaviour in rats VI: the effects of ethanol and selective serotonergic drugs on response choice with varying delays of reinforcement. *Psychopharmacology (Berl).* 1999; 146:413–421. [PubMed: 10550491]
20. Blokland A, Sik A, Lieben C. Evaluation of DOI, 8-OH-DPAT, eticlopride and amphetamine on impulsive responding in a reaction time task in rats. *Behav.Pharmacol.* 2005; 16:93–100. [PubMed: 15767844]
21. Carli M, Samanin R. The 5-HT(1A) receptor agonist 8-OH-DPAT reduces rats' accuracy of attentional performance and enhances impulsive responding in a five-choice serial reaction time task: role of presynaptic 5-HT(1A) receptors. *Psychopharmacology (Berl).* 2000; 149:259–268. [PubMed: 10823407]
22. Evenden JL. The pharmacology of impulsive behaviour in rats IV: the effects of selective serotonergic agents on a paced fixed consecutive number schedule. *Psychopharmacology (Berl).* 1998; 140:319–330. [PubMed: 9877012]
23. Hadamitzky M, Koch M. Effects of acute intra-cerebral administration of the 5-HT(2A/C) receptor ligands DOI and ketanserin on impulse control in rats. *Behav.Brain Res.* 2009; 204:88–92. [PubMed: 19467270]
24. Koskinen T, Ruotsalainen S, Sirvio J. The 5-HT(2) receptor activation enhances impulsive responding without increasing motor activity in rats. *Pharmacol Biochem.Behav.* 2000; 66:729–738. [PubMed: 10973510]
25. Koskinen T, Ruotsalainen S, Puumala T, Lappalainen R, Koivisto E, Mannisto PT, Sirvio J. Activation of 5-HT<sub>2A</sub> receptors impairs response control of rats in a five-choice serial reaction time task. *Neuropharmacology.* 2000; 39:471–481. [PubMed: 10698013]
26. Koskinen T, Haapalinna A, Sirvio J. Alpha-adrenoceptor-mediated modulation of 5-HT<sub>2</sub> receptor agonist induced impulsive responding in a 5-choice serial reaction time task. *Pharmacol Toxicol.* 2003; 92:214–225. [PubMed: 12753409]
27. Young JW, Powell SB, Scott CN, Zhou X, Geyer MA. The effect of reduced dopamine D<sub>4</sub> receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. *Behav.Brain Res.* 2011; 222:183–192. [PubMed: 21458500]
28. Chudasama Y, Passetti F, Rhodes SE, Lopian D, Desai A, Robbins TW. Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity. *Behav.Brain Res.* 2003; 146:105–119. [PubMed: 14643464]


29. Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. *Neuron*. 2011; 69:680–694. [PubMed: 21338879]
30. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A, Sahakian BJ, Robbins TW, Bullmore ET, Hollander E. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. *Neuropsychopharmacology*. 2010; 35:591–604. [PubMed: 19940844]
31. Cunningham KA, Anastasio NC. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. *Neuropharmacology*. 2014; 76(Pt B):460–478. [PubMed: 23850573]
32. Amargos-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Toth M, Mengod G, Artigas F. Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex. *Cereb.Cortex*. 2004; 14:281–299. [PubMed: 14754868]
33. Burnet PWJ, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor mRNA in human brain. *Brain Res*. 1995; 676:157–168. [PubMed: 7796165]
34. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT. Regional distribution and cellular localization of 5-HT<sub>2C</sub> receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. *Synapse*. 2001; 42:12–26. [PubMed: 11668587]
35. Pompeiano M, Palacios JM, Mengod G. Distribution of the serotonin 5-HT<sub>2</sub> receptor family mRNAs: Comparison between 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *Mol.Brain Res*. 1994; 23:163–178. [PubMed: 8028479]
36. Nocjar C, Alex KD, Sonneborn A, Abbas AI, Roth BL, Pehek EA. Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex. *Neuroscience*. 2015; 297:22–37. [PubMed: 25818050]
37. Wischhof L, Hollensteiner KJ, Koch M. Impulsive behaviour in rats induced by intracortical DOI is antagonized by co-administration of an mGlu2/3 receptor agonist. *Behav.Pharmacol*. 2011; 22:805–813. [PubMed: 22015807]
38. Winstanley CA, Chudasama Y, Dalley JW, Theobald DE, Glennon JC, Robbins TW. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. *Psychopharmacology (Berl)*. 2003; 167:304–314. [PubMed: 12677356]
39. Beique JC, Imad M, Mladenovic L, Gingrich JA, Andrade R. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. *Proc.Natl.Acad.Sci.U.S.A*. 2007; 104:9870–9875. [PubMed: 17535909]
40. Anastasio NC, Lanfranco MF, Bubar MJ, Seitz PK, Stutz SJ, McGinnis AG, Watson CS, Cunningham KA. Serotonin 5-HT<sub>2C</sub> receptor protein expression is enriched in synaptosomal and post-synaptic compartments of rat cortex. *J.Neurochem*. 2010; 113:1504–1515. [PubMed: 20345755]
41. Becamel C, Gavarini S, Chanrion B, Alonso G, Galeotti N, Dumuis A, Bockaert J, Marin P. The serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors interact with specific sets of PDZ proteins. *J Biol.Chem*. 2004; 279:20257–20266. [PubMed: 14988405]
42. Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. *Neuroscience*. 2003; 116:107–117. [PubMed: 12535944]
43. Gyls KH, Fein JA, Cole GM. Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry. *J Neurosci Res*. 2000; 61:186–192. [PubMed: 10878591]
44. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT. Selective visualization of rat brain 5-HT<sub>2A</sub> receptors by autoradiography with [3H]MDL 100,907. *Naunyn Schmiedebergs Arch.Pharmacol*. 1997; 356:446–454. [PubMed: 9349630]
45. Mengod G, Vilaro MT, Raurich A, Lopez-Gimenez JF, Cortes R, Palacios JM. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. *Histochem.J*. 1996; 28:747–758. [PubMed: 8968727]
46. de Almeida J, Mengod G. Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. *J.Neurochem*. 2007; 103:475–486. [PubMed: 17635672]

47. Carr DB, Cooper DC, Ulrich SL, Spruston N, Surmeier DJ. Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. *J Neurosci.* 2002; 22:6846–6855. [PubMed: 12177182]
48. Robinson ES, Dalley JW, Theobald DE, Glennon JC, Pezze MA, Murphy ER, Robbins TW. Opposing roles for 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. *Neuropsychopharmacology.* 2008; 33:2398–2406. [PubMed: 18046307]
49. Robbins TW. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. *Psychopharmacology (Berl).* 2002; 163:362–380. [PubMed: 12373437]
50. Robbins TW, McAlonan G, Muir JL, Everitt BJ. Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. *Behav Brain Res.* 1997; 83:15–23. [PubMed: 9062655]
51. Evenden JL. Impulsivity: a discussion of clinical and experimental findings. *J Psychopharmacol.* 1999; 13:180–192. [PubMed: 10475725]
52. Frijda NH. Impulsive action and motivation. *Biol.Psychol.* 2010; 84:570–579. [PubMed: 20064583]
53. Soubrié P. Reconciling the role of central serotonin neurons in human and animal behavior. *Behavioral and Brain Sciences.* 1986:319–364.
54. Van der Kooy D, Fibiger HC, Phillips AG. An analysis of dorsal and median raphe self-stimulation: effects of parachlorophenylalanine. *Pharmacol.Biochem.Behav.* 1978; 8:441–445. [PubMed: 149989]
55. Simon H, Le MM, Cardo B. Intracranial self-stimulation from the dorsal raphe nucleus of the rat: effects of the injection of para-chlorophenylalanine and of alpha-methylparatyrosine. *Behav.Biol.* 1976; 16:353–364. [PubMed: 132167]
56. Miliareisis E. Serotonergic basis of reward in median raphe of the rat. *Pharmacol.Biochem.Behav.* 1977; 7:177–180. [PubMed: 144276]
57. Worbe Y, Savulich G, Voon V, Fernandez-Egea E, Robbins TW. Serotonin depletion induces 'waiting impulsivity' on the human four-choice serial reaction time task: cross-species translational significance. *Neuropsychopharmacology.* 2014; 39:1519–1526. [PubMed: 24385133]
58. Clark L, Roiser J, Cools R, Rubinsztein D, Sahakian B, Robbins T. Stop signal response inhibition is not modulated by tryptophan depletion or the serotonin transporter polymorphism in healthy volunteers: implications for the 5-HT theory of impulsivity. *Psychopharmacology.* 2005; 182:570–578. [PubMed: 16163530]
59. Harrison AA, Everitt BJ, Robbins TW. Doubly dissociable effects of median- and dorsal-raphé lesions on the performance of the five-choice serial reaction time test of attention in rats. *Behav.Brain Res.* 1997; 89:135–149. [PubMed: 9475622]
60. Winstanley CA, Dalley JW, Theobald DE, Robbins TW. Fractionating impulsivity: contrasting effects of central 5-HT depletion on different measures of impulsive behavior. *Neuropsychopharmacology.* 2004; 29:1331–1343. [PubMed: 15054475]
61. Dalley JW, Theobald DE, Eagle DM, Passetti F, Robbins TW. Deficits in impulse control associated with tonically-elevated serotonergic function in rat prefrontal cortex. *Neuropsychopharmacology.* 2002; 26:716–728. [PubMed: 12007742]
62. Puumala T, Sirviö J. Changes in activities of dopamine and serotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task. *Neuroscience.* 1998; 83:489–499. [PubMed: 9460757]
63. Lambe EK, Fillman SG, Webster MJ, Shannon WC. Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development. *PLoS.One.* 2011; 6:e22799. [PubMed: 21829518]
64. Garoflos E, Stamatakis A, Mantelas A, Philippidis H, Stylianopoulou F. Cellular mechanisms underlying an effect of "early handling" on pCREB and BDNF in the neonatal rat hippocampus. *Brain Research.* 2005; 1052:187–195. [PubMed: 16024004]
65. Mitchell JB, Iny LJ, Meaney MJ. The role of serotonin in the development and environmental regulation of type II corticosteroid receptor binding in rat hippocampus. *Dev.Brain Res.* 1990; 55:231–235. [PubMed: 1701365]




66. Smythe JW, Rowe WB, Meaney MJ. Neonatal handling alters serotonin (5-HT) turnover and 5-HT<sub>2</sub> receptor binding in selected brain regions: Relationship to the handling effect on glucocorticoid receptor expression. *Dev. Brain Res.* 1994; 80:183–189. [PubMed: 7525113]
67. Benekareddy M, Goodfellow NM, Lambe EK, Vaidya VA. Enhanced function of prefrontal serotonin 5-HT<sub>2</sub> receptors in a rat model of psychiatric vulnerability. *J. Neurosci.* 2010; 30:12138–12150. [PubMed: 20826676]
68. Jupp B, Caprioli D, Dalley JW. Highly impulsive rats: modelling an endophenotype to determine the neurobiological, genetic and environmental mechanisms of addiction. *Disease models & mechanisms.* 2013; 6:302–311. [PubMed: 23355644]
69. Simon NW, Beas BS, Montgomery KS, Haberman RP, Bizon JL, Setlow B. Prefrontal cortical-striatal dopamine receptor mRNA expression predicts distinct forms of impulsivity. *Eur J Neurosci.* 2013; 37:1779–1788. [PubMed: 23510331]
70. Wischhof L, Koch M. Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression. *Psychopharmacology (Berl).* 2012; 219:387–400. [PubMed: 21863235]
71. Higgins GA, Enderlin M, Haman M, Fletcher PJ. The 5-HT<sub>2A</sub> receptor antagonist M100,907 attenuates motor and 'impulsive-type' behaviours produced by NMDA receptor antagonism. *Psychopharmacology (Berl).* 2003; 170:309–319. [PubMed: 12904968]
72. Carli M, Invernizzi RW. Serotonergic and dopaminergic modulation of cortico-striatal circuit in executive and attention deficits induced by NMDA receptor hypofunction in the 5-choice serial reaction time task. *Front Neural Circuits.* 2014; 8:58. [PubMed: 24966814]
73. Burton CL, Fletcher PJ. Age and sex differences in impulsive action in rats: the role of dopamine and glutamate. *Behav Brain Res.* 2012; 230:21–33. [PubMed: 22326372]
74. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. *J Pharmacol Exp Ther.* 2000; 292:76–87. [PubMed: 10604933]
75. Dougherty JP, Aloyo VJ. Pharmacological and behavioral characterization of the 5-HT<sub>2A</sub> receptor in C57BL/6N mice. *Psychopharmacology (Berl).* 2011; 215:581–593. [PubMed: 21340474]
76. Puig MV, Gullledge AT. Serotonin and prefrontal cortex function: neurons, networks, and circuits. *Mol Neurobiol.* 2011; 44:449–464. [PubMed: 22076606]
77. Fink KB, Gothert M. 5-HT receptor regulation of neurotransmitter release. *Pharmacol. Rev.* 2007; 59:360–417. [PubMed: 18160701]
78. Stephens EK, Avesar D, Gullledge AT. Activity-dependent serotonergic excitation of callosal projection neurons in the mouse prefrontal cortex. *Front Neural Circuits.* 2014; 8:97. [PubMed: 25206322]
79. Avesar D, Gullledge AT. Selective serotonergic excitation of callosal projection neurons. *Front Neural Circuits.* 2012; 6:12. [PubMed: 22454619]
80. Celada P, Puig MV, Artigas F. Serotonin modulation of cortical neurons and networks. *Frontiers in integrative Neuroscience.* 2013; 7:25. [PubMed: 23626526]
81. Sheldon PW, Aghajanian GK. Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: Evidence for mediation by 5-HT<sub>1C</sub> receptors in pyramidal cells and 5-HT<sub>2</sub> receptors in interneurons. *Synapse.* 1991; 9:208–218. [PubMed: 1776132]
82. Beique JC, Campbell B, Perring P, Hamblin MW, Walker P, Mladenovic L, Andrade R. Serotonergic regulation of membrane potential in developing rat prefrontal cortex: coordinated expression of 5-hydroxytryptamine (5-HT)<sub>1A</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>7</sub> receptors. *J Neurosci.* 2004; 24:4807–4817. [PubMed: 15152041]
83. Liu S, Bubar MJ, Lanfranco MF, Hillman GR, Cunningham KA. Serotonin<sub>2C</sub> receptor localization in GABA neurons of the rat medial prefrontal cortex: Implications for understanding the neurobiology of addiction. *Neuroscience.* 2007; 146:1667–1688.
84. Hasbi A, O'Dowd BF, George SR. Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance. *Mol. Brain.* 2011; 4:26. [PubMed: 21663703]
85. Frederick AL, Yano H, Trifilieff P, Vishwasrao HD, Biezonski D, Meszaros J, Urizar E, Sibley DR, Kellendonk C, Sonntag KC, Graham DL, Colbran RJ, Stanwood GD, Javitch JA. Evidence against dopamine D1/D2 receptor heteromers. *Mol Psychiatry.* 2015

86. Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. *FASEB J.* 2007; 21:2455–2465. [PubMed: 17384143]
87. Fujita W, Gomes I, Devi LA. Revolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10. *Br J Pharmacol.* 2014; 171:4155–4176. [PubMed: 24916280]
88. Bubar MJ, Cunningham KA. Prospects for serotonin 5-HT<sub>2</sub>R pharmacotherapy in psychostimulant abuse. *Prog. Brain Res.* 2008; 172:319–346. [PubMed: 18772040]
89. Liu S-B, Sardi S, Sonom B, Zocco D, McSweeney R, Fraser AD, Halleck AE, Li H, Smeljkal GB, Munevar S, Jin JG, Kawai T, Ghiran I, McGrath JP, Whitman M, Ng S-W, Kuo WP. The application of a novel nanovolume capillary electrophoresis-based protein analysis system in personalized & translational medicine research. *J Bioanal Biomed S3.* 2013
90. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ. Local gene knockdown in the brain using viral-mediated RNA interference. *Nat. Med.* 2003; 9:1539–1544. [PubMed: 14634645]
91. Paxinos, W.; Watson, C. *The Rat Brain in Stereotaxic Coordinates*. 4th. San Diego CA: Academic Press; 1998.
92. Daly TM. Overview of adeno-associated viral vectors. *Methods Mol. Biol.* 2004; 246:157–165. [PubMed: 14970590]
93. Leff SE, Spratt SK, Snyder RO, Mandel RJ. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. *Neuroscience.* 1999; 92:185–196. [PubMed: 10392841]
94. Li X, Wolf ME. Visualization of virus-infected brain regions using a GFP-illuminating flashlight enables accurate and rapid dissection for biochemical analysis. *J. Neurosci. Methods.* 2011
95. Bubar MJ, Stutz SJ, Cunningham KA. 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway. *PLoS. One.* 2011; 6:e20508. [PubMed: 21687728]




**Figure 1. Phenotypic stratification of motor impulsivity with the 1-CSRT task**

[A] The number of premature responses made during the IT18 challenge session was used to stratify rats as high impulsive (HI, upper quartile) or low impulsive (LI, lower quartile) relative to mid impulsive (MI, middle two quartiles) rats. [B] HI rats displayed higher premature responses ( $*p < 0.001$  vs. LI), [C] earned fewer reinforcers ( $*p < 0.05$  vs. LI), and [D] made fewer omissions relative to LI rats ( $*p < 0.05$  vs. LI).





**Figure 2. Inherent motor impulsivity predicts mPFC 5-HT<sub>2A</sub>:5-HT<sub>2C</sub> synaptosomal protein profile**

Following 1-CSRT task training and phenotypic identification, the mPFC was collected for biochemical analysis. Immunoblots for the [A inset] 5-HT<sub>2A</sub>R, [B inset] 5-HT<sub>2C</sub>R and [A and B inset] cadherin loading control were performed using crude synaptosomal protein from the mPFC. Densitometric quantitation revealed [A] higher 5-HT<sub>2A</sub>R, [B] lower 5-HT<sub>2C</sub>R, and [C] a heightened ratio of 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R protein expression in HI relative to LI rats (\**p*<0.05 vs. LI). There was a correlation between [D] premature responses and 5-HT<sub>2A</sub>R protein expression ( $r^2=0.373$ ; *p*<0.05), [E] premature responses and 5-HT<sub>2C</sub>R protein expression ( $r^2=0.512$ ; *p*<0.001), and [F] premature responses and the 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R ratio ( $r^2=0.537$ ; *p*<0.001).



**Figure 3. The 5-HT<sub>2A</sub>R:5-HT<sub>2C</sub>R mPFC protein complex is disrupted in high motor impulsivity**  
Following 1-CSRT task training and phenotypic identification, the mPFC was collected for biochemical analysis. **[A]** Immunoprecipitation (IP) for 5-HT<sub>2C</sub>R followed by immunoblot (IB) for 5-HT<sub>2A</sub>R yielded 5-HT<sub>2A</sub>R immunoreactivity in both HI and LI rats. **[B]** Immunoprecipitation for 5-HT<sub>2A</sub>R and IB for 5-HT<sub>2C</sub>R yielded 5-HT<sub>2C</sub>R immunoreactivity in both HI and LI rats. **[A and B]** Qualitative (insets) and quantitative demonstration that synaptosomal 5-HT<sub>2C</sub>R associates with 5-HT<sub>2A</sub>R in the mPFC to a lesser extent in HI relative to LI rats (\**p* < 0.05). The insets are representative electrophoretic bands. Arbitrary units (A.U.) of densitometry are presented.





**Figure 5. Knockdown of mPFC 5-HT<sub>2C</sub>R recapitulates high motor impulsivity and enhances 5-HT<sub>2A</sub>R regulation of motor impulsivity**

Following stable viral vector expression and 1-CSRT task training, the effects of M100907 (0.001, 0.01, and 0.1 mg/kg) were evaluated under ITI5 conditions. **[A]** Baseline levels of premature responses in 5-HT<sub>2C</sub>R knockdown rats administered vehicle (VEH; ▲, dashed line) were significantly higher than the vehicle baseline in control rats (○, dotted line; \* $p < 0.05$  vs. NSC-eGFP AAV-VEH). In the 5-HT<sub>2C</sub>R knockdown rats, M100907 significantly suppressed premature responses at 0.01 and 0.1 mg/kg (# $p < 0.05$  vs. 5-HT<sub>2C</sub>R shRNA-eGFP AAV-VEH), below the vehicle baseline of control rats. **[B]** Baseline levels of reinforcers earned in 5-HT<sub>2C</sub>R knockdown rats administered vehicle (VEH; ▲, dashed line) did not differ from the vehicle baseline in control rats (○, dotted line). M100907 significantly increased the number of reinforcers earned at 0.01 and 0.1 mg/kg (# $p < 0.05$  vs. 5-HT<sub>2C</sub>R shRNA-eGFP AAV-VEH), above the vehicle baseline of control rats. **[C]** Baseline levels of omissions in 5-HT<sub>2C</sub>R knockdown rats administered vehicle (VEH; ▲, dashed line) did not differ from the vehicle baseline in control rats (○, dotted line). M100907 did not alter the number of percent omissions in 5-HT<sub>2C</sub>R knockdown or control rats.